Document Detail

What the statin trials have taught us.
MedLine Citation:
PMID:  16784935     Owner:  NLM     Status:  MEDLINE    
It has taken a century since Anitschkow began feeding cholesterol to rabbits to study the role of cholesterol in atherosclerosis to be fully appreciated and for the potential of cholesterol reduction to prevent cardiovascular events to be fully realized. The body of clinical trial data testing the effects of statins on coronary heart disease is extensive and convincing. A 1% reduction in low-density lipoprotein cholesterol reduces coronary events by approximately 1%. With large doses of potent statins, low-density lipoprotein cholesterol levels and coronary events can thus be reduced by approximately 50%. The anti-inflammatory effects of large doses of atorvastatin likely contribute to the early event reduction seen early after acute coronary syndromes. Translating this information into clinical practice presents a challenge: many patients who would benefit from statins remain untreated or undertreated or discontinue treatment soon after it is initiated.
David D Waters
Related Documents :
17652885 - Randomized trial of statin administration for myocardial injury: is intensive lipid-low...
3295315 - Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis an...
2215615 - Regression of coronary artery disease as a result of intensive lipid-lowering therapy i...
9412775 - Stabilization of atherosclerotic plaque during lipid lowering.
14701945 - Absence of factor v leiden (g1691a) mutation, fii g20210a allele in coronary artery dis...
10539825 - Lack of effect of recent alcohol consumption on the course of acute myocardial infarction.
Publication Detail:
Type:  Editorial     Date:  2006-05-06
Journal Detail:
Title:  The American journal of cardiology     Volume:  98     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-06-20     Completed Date:  2006-08-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  129-34     Citation Subset:  AIM; IM    
Division of Cardiology, San Francisco General Hospital, California, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cholesterol, LDL / drug effects*
Coronary Disease / drug therapy*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology,  therapeutic use*
Randomized Controlled Trials as Topic
Treatment Outcome
Reg. No./Substance:
0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular dis...
Next Document:  Coronary artery disease prognosis and C-reactive protein levels improve in proportion to percent low...